The Intracellular Neurotransmitter 5-HT Acts Through Activating YAP to Promote the Carcinogenesis of Colorectal Cancer

HF Yu,HW Xia,HJ Xu,QL Tang,QY Gong,Y Nie,F Bi
DOI: https://doi.org/10.2139/ssrn.3369739
2019-01-01
SSRN Electronic Journal
Abstract:Background: 5-hydroxytryptamine (5-HT, serotonin), a well-known neurotransmitter, plays a vital role in the physiological and pathological regulation of the central nervous system and gastrointestinal tract. Recently, emerging evidences indicate that 5-HT also plays an important role in tumorigenesis, but little is known about its role in colorectal cancer. Methods: By using western blot, immunofluorescent staining, GST pulldown assay, gene interference and LC-MS/MS assays, we investigated the effect and mechanism of 5-HT on the malignancies of the two colon cell lines (SW480 and SW1116 cells) in vitro. We then evaluated the role of 5-HT in tumorigenesis in vivo and the clinical significance of two pivotal proteins of 5-HT signal in human colon cancer tissues. Findings: 5-HT could be transported into cells via SERT, enhancing YAP expression and promoting colon cancer cell growth in vitro and in vivo. Further study revealed that intracellular 5-HT transported by SERT serotonylated and activated RhoA under the catalysation of TG2, subsequently through activating the RhoA-ROCK1/2 signalling to upregulate YAP expression in SW480 and SW1116 cells. Blocking SERT with citalopram reversed the 5-HT-induced YAP expression and cell proliferation, and inhibited the effects of 5-HT on tumour formation in mice. Moreover, SERT expression was correlated with YAP in pathological human colorectal cancer samples. Interpretation: Our findings suggested that 5-HT could enter cells via SERT transportation to activate the RhoA/ROCK/YAP signalling to promote the carcinogenesis of colon cancer. Thus, targeting 5-HT-SERT-YAP axis may be a potential therapeutic strategy for colon cancer. Funding Statement: This work was supported by grants from the National Key R&D Program of China(No. 2016YFC1303200/2016YFC1303203), the National Natural Science Foundation of China(No. 81872020, 81621003). Declaration of Interests: The authors declare no conflict of interest associated with this manuscript. Ethics Approval Statement: The animal studies were carried out in accordance to guidelines established by the State Key Laboratory of Biotherapy Institutional Animal Experimental Ethics Committee (approval no. 20160017)
What problem does this paper attempt to address?